In a significant regulatory and legal development, four Danish patients who suffered permanent vision damage after using Novo Nordisk’s GLP-1 receptor agonists—Wegovy and Ozempic—have been awarded a combined DKK 800,000 in compensation by the Danish Patient Compensation Fund. This marks the first formal acknowledgments of liability in what is now a growing cohort of 43 reported cases under review.
The compensation stems from confirmed diagnoses of non-arteritis anterior ischemic optic neuropathy (NAION)—a rare but serious eye condition that can cause sudden, irreversible vision loss or visual field defects. Three of the compensated patients used Wegovy, Novo Nordisk’s blockbuster weight-loss drug, while one used Ozempic, a closely related medication approved for type 2 diabetes management. Both contain the active ingredient semaglutide.
From Denial to Regulatory Recognition
Until late 2024, NAION was not listed as a potential side effect of semaglutide-based therapies. However, mounting evidence from two large-scale Danish registry studies—conducted by researchers including Professor Kurt Højlund of Steno Diabetes Centre Odense—revealed a statistically significant association between semaglutide use and an elevated risk of NAION, particularly within the first 14 months of treatment. In response, the Danish Medicines Agency escalated its findings to the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) in December 2024.
Despite initial resistance from Novo Nordisk, which publicly maintained in early 2024 that “available data does not show a reasonable probability of a causal relationship,” the EMA’s Committee for Medicinal Products for Human Use (CHMP) formally classified NAION as a “very rare” adverse reaction in October 2025. This designation applies to side effects occurring in fewer than 1 in 10,000 patients.
High-Risk Profiles and Clinical Guidance
The Danish Medicines Agency emphasizes that individuals with preexisting risk factors—including type 2 diabetes, hypertension, hyperlipidaemia, and severe obesity—are particularly vulnerable to NAION. Intriguingly, emerging data also suggest that the risk appears concentrated in the early phase of treatment: patients who have taken semaglutide for more than 14 months without incident show no increased likelihood of developing the condition.
Professor Højlund has advised clinicians to discontinue semaglutide immediately if NAION is diagnosed in one eye, given the potential for bilateral involvement. “While the absolute risk remains low,” he noted, “the consequences are severe and irreversible—making vigilance essential.”
Compensation Despite Informed Consent
Under Denmark’s Patient Compensation Act, individuals are entitled to state-funded compensation for serious and rare adverse drug reactions—even if the risk was known at the time of treatment. As such, the DKK 800,000 payout, administered by the Ministry of the Interior and Health, reflects a legal acknowledgment of harm rather than negligence. Notably, liability falls on the state, not Novo Nordisk, consistent with Denmark’s no-fault compensation framework for pharmaceutical injuries.
Broader Implications for the Pharmaceutical Sector
This case underscores the evolving challenges in pharmacovigilance for high-volume medications. With over 260,000 Danes having received Wegovy prescriptions since its 2022 market launch, even very rare side effects can translate into significant public health and financial impacts. For Novo Nordisk—whose GLP-1 drugs generated over DKK 100 billion in global revenue in 2024—the regulatory reclassification of NAION may prompt updates to prescribing guidelines, risk communication strategies, and insurance considerations across European markets.
Moreover, the case highlights the critical role of national health registries in post-marketing surveillance. Denmark’s integrated healthcare data systems enabled the rapid detection of a signal that might have remained obscured in less granular datasets—a testament to the Nordic model’s value in ensuring drug safety at scale.
Looking Ahead
With 38 additional NAION-related compensation claims still pending, this issue is far from resolved. Healthcare providers are urged to screen patients for ocular and vascular risk factors before initiating semaglutide therapy and to counsel them on early warning signs—such as sudden, painless vision loss upon waking.
For now, the Danish authorities have struck a balance: affirming patient safety without undermining confidence in a class of medications that has transformed metabolic care for millions. But as real-world evidence accumulates, ongoing scrutiny will remain essential—not just in Denmark, but across the global markets racing to adopt GLP-1 therapies.
Reporting by the Nordic Business Journal. Sources: Danish Patient Compensation Fund, Danish Medicines Agency, European Medicines Agency, Steno Diabetes Centre Odense.